Clinical Trial Update: SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study updating SKB264 with or without KL-A167 for recurrent/metastatic HER2-negative breast cancer, including triple-negative and HR+/HER2- subtypes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• KL-A167
• SKB264

Snippet

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Conditions: Triple-negative Breast Cancer and HR+/HER2- BC | Phase 2 | Status: ACTIVE_NOT_RECRUITING